Study Shows Women with Heart Failure Lose More Weight on Semaglutide than Men
Advertisement
According to new research presented at the American Diabetes Association's 2024 Scientific Sessions and published in the Journal of the American College of Cardiology (JACC), Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options. Women experienced greater weight loss and the same symptom benefits compared with men.
Obesity-related heart failure with preserved ejection fraction (HFpEF) is the most common type of HFpEF, and it is becoming a bigger problem worldwide, causing more illness and death.
Research shows that excess belly fat leads to changes in the body that contribute to both the development and worsening of heart failure, especially in women. People with obesity-related HFpEF have more severe heart failure symptoms, poorer functional status, a lower quality of life, and worse clinical outcomes compared to those without obesity. Therefore, there is an urgent need to develop effective and safe treatments specifically designed for obesity-related heart failure.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.